A Lithuanian CDMO is investing €50 million in its biologics manufacturing site and adding up to 80 jobs.

Chinese CDMO GenScript Biotech has started construction on a production facility to specialize in plasmids and viruses manufacturing.

Ajinomoto Bio-Pharma Services has concluded a deal that will allow the CDMO to operate in the gene therapy space.

In the second major buyout of a gene therapy manufacturer in the last three weeks, Catalent snapped up Paragon Bioservices in a $1.2 billion deal.

Cambrex will have a new U.S. facility capable of producing high-potency APIs ready and running in May.

A man who made tens of millions of dollars selling gray-market drugs in the U.S. has been sentenced to 30 years in federal prison.

Fresenius Kabi missed an opportunity to quickly bulk up in sterile manufacturing when its $5 billion deal to buy Akorn imploded last year.

Even as Aurobindo grows its footprint in the U.S., the FDA continues to find problems in its manufacturing.